Latest Mitral valve Stories

OR YEHUDA, Israel, May 16, 2013 /PRNewswire/ -- Valtech Cardio Ltd., a medical device company that develops solutions for mitral valve repair and replacement, announced today that two patients diagnosed with severe mitral regurgitation (MR) have been treated successfully with the Transfemoral Cardioband(TM) Annuloplasty System. (Photo: http://photos.prnewswire.com/prnh/20130516/613819 ) The Cardioband device replaces the need for open-heart surgery for MR...

INDIANAPOLIS, April 11, 2013 /PRNewswire-USNewswire/ -- Franciscan St. Francis Health is the first hospital in the United States to implant a new device that could improve the quality of life for patients with aortic valve disease. The On-X® Aortic Prosthetic Valve with Anatomic Sewing Ring is the most advanced mechanical heart valve and first to address the important concern of distorting the adjacent structures within the heart. The innovative valve is the only mechanical valve...

ABBOTT PARK, Ill., March 20, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has voted by majority (Yes: 5, No: 3) that the benefits of treatment with the MitraClip(®) device outweigh its risks in patients with significant symptomatic mitral regurgitation (MR) who have been determined by a cardiac surgeon to be too high risk for open mitral valve...

SAN FRANCISCO, March 10, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced data from the EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High Surgical Risk cohort evaluating the company's first-in-class catheter-based MitraClip(®) System for the treatment of mitral regurgitation (MR). Findings were presented today at the 62nd Annual Scientific Session of the American College of Cardiology in San Francisco. Abbott's MitraClip system, an investigational device in the...

Third European Multi-Center Study Validating Earlier Compelling Results KIRKLAND, Wash., March 8, 2013 /PRNewswire/ -- Cardiac Dimensions(®),( )Inc. today announced that it has completed enrollment in its TITAN II clinical trial, a follow-up to the landmark TITAN clinical trial of the Company's CARILLON(® )Mitral Contour System(®). TITAN II is a prospective, single-arm European multi-center clinical trial initiated to further evaluate an enhanced version of the...

WILMINGTON, Del. and MUNICH, Feb. 4, 2013 /PRNewswire/ -- JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter-delivered aortic valve systems (TAVI) for the treatment of aortic valve disease, announced today that it has appointed veteran medical device engineering executive John F. Migliazza as Chief Operating Officer, effective February 4. Migliazza will report directly to Chief Executive Officer Helmut J. Straubinger....

CHICAGO, Jan. 14, 2013 /PRNewswire/ -- Phoenix Cardiac Devices, Inc., a medical device company with a novel method of repairing leaky heart valves without open-heart surgery, has enrolled its first patient in a clinical trial aimed at achieving CE Mark approval in Europe. The trial will assess the safety and efficacy of the BACE(TM) device, an adjustable tension band that encircles the heart and supports the mitral valve leaflets so they close properly to prevent the back flow of...

BETHLEHEM, Pa., Jan. 14, 2013 /PRNewswire/ -- Micro Interventional Devices, Inc.(TM) (MID), an emerging cardiovascular medical device company, announced today it has secured $3.5 million of its expected $5 million Series B financing. The initial tranche was led by Originate Ventures with existing investor, Battelle Ventures, LP, also participating in the round. In conjunction with the financing Mike Gausling, Managing Partner of Originate Ventures, will join the MID Board of...

New "staged left ventricle recruitment," or SLVR, approach could revolutionize treatment of severe form of congenital heart defect BOSTON, Nov. 6, 2012 /PRNewswire-USNewswire/ -- Using a combination of surgical procedures developed over the last 11 years, surgeons at Boston Children's Hospital have established a new approach for rebuilding the heart in children born with a severe heart defect called hypoplastic left heart syndrome (HLHS). This "staged left ventricle recruitment"...

--Neovasc is Supplying Product During Transition and will Redirect Freed-Up Manufacturing Capacity to Support Growing Sales to Transcatheter Heart Valve Customers-- --Proceeds from Sale of Rights Will Help Fund Neovasc's Key Development Projects-- TSX Venture Exchange: NVC VANCOUVER, Nov. 1, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that it has finalized its agreement with LeMaitre Vascular, Inc. (Nasdaq: LMAT) allowing LeMaitre to exercise its option to...